Atea Pharmaceuticals, Inc. Comprehensive Income
Atea Pharmaceuticals, Inc. (AVIR) reported Comprehensive Income of -$32.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$32.93M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$45.71M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$44.93M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$41.85M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$158.41M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$168.36M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$135.06M.
- Atea Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$116.59M, a 196.21% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$32.93M 10-Q · filed 2026-08-12 | -$78.64M 10-Q · filed 2026-08-12 | -$123.57M derived: sum of 3 quarters · filed 2026-08-12 | -$165.42M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$45.71M 10-Q · filed 2026-05-12 | -$90.64M derived: sum of 2 quarters · filed 2026-05-12 | -$132.49M derived: sum of 3 quarters · filed 2026-05-12 | -$169.73M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$44.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$86.78M derived: sum of 2 quarters · filed 2026-03-05 | -$124.02M derived: sum of 3 quarters · filed 2026-08-12 | -$158.41M 10-K · filed 2026-03-05 | |
| 2025-09-30 | -$41.85M 10-Q · filed 2025-11-12 | -$79.09M derived: sum of 2 quarters · filed 2026-08-12 | -$113.48M 10-Q · filed 2025-11-12 | -$147.43M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$37.24M 10-Q · filed 2026-08-12 | -$71.63M 10-Q · filed 2026-08-12 | -$105.58M derived: sum of 3 quarters · filed 2026-08-12 | -$135.81M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$34.39M 10-Q · filed 2026-05-12 | -$68.34M derived: sum of 2 quarters · filed 2026-05-12 | -$98.57M derived: sum of 3 quarters · filed 2026-05-12 | -$139.19M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$33.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$64.18M derived: sum of 2 quarters · filed 2026-03-05 | -$104.80M derived: sum of 3 quarters · filed 2026-03-05 | -$168.36M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$30.23M 10-Q · filed 2025-11-12 | -$70.85M derived: sum of 2 quarters · filed 2025-11-12 | -$134.41M 10-Q · filed 2025-11-12 | -$173.10M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$40.62M 10-Q · filed 2025-08-07 | -$104.18M 10-Q · filed 2025-08-07 | -$142.87M derived: sum of 3 quarters · filed 2025-08-07 | -$175.97M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$63.56M 10-Q · filed 2025-05-12 | -$102.25M derived: sum of 2 quarters · filed 2025-05-12 | -$135.35M derived: sum of 3 quarters · filed 2025-05-12 | -$163.53M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$38.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$71.79M derived: sum of 2 quarters · filed 2025-03-06 | -$99.97M derived: sum of 3 quarters · filed 2025-03-06 | -$135.06M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$33.09M 10-Q · filed 2024-11-07 | -$61.28M derived: sum of 2 quarters · filed 2024-11-07 | -$96.37M 10-Q · filed 2024-11-07 | -$130.63M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$28.19M 10-Q · filed 2024-08-07 | -$63.28M 10-Q · filed 2024-08-07 | -$97.54M derived: sum of 3 quarters · filed 2024-08-07 | -$106.46M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | -$35.09M 10-Q · filed 2024-05-14 | -$69.35M derived: sum of 2 quarters · filed 2024-05-14 | -$78.27M derived: sum of 3 quarters · filed 2024-05-14 | -$109.61M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$34.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$43.18M derived: sum of 2 quarters · filed 2024-02-28 | -$74.52M derived: sum of 3 quarters · filed 2024-02-28 | -$116.59M 10-K · filed 2024-02-28 | |
| 2022-09-30 | -$8.92M 10-Q · filed 2023-11-08 | -$40.26M derived: sum of 2 quarters · filed 2023-11-08 | -$82.33M 10-Q · filed 2023-11-08 | $34.80M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$31.34M 10-Q · filed 2023-08-08 | -$73.41M 10-Q · filed 2023-08-08 | $43.72M derived: sum of 3 quarters · filed 2023-08-08 | $15.53M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$42.08M 10-Q · filed 2023-05-08 | $75.06M derived: sum of 2 quarters · filed 2023-05-08 | $46.86M derived: sum of 3 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $117.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $88.94M derived: sum of 2 quarters · filed 2023-02-28 | $121.19M 10-K · filed 2023-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2021-09-30 | -$28.19M 10-Q · filed 2022-11-07 | $4.06M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | -$10.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$10.95M derived: sum of 2 quarters · filed 2023-02-28 | -$10.95M 10-K · filed 2023-02-28 | $0.00 10-K · filed 2021-03-30 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-12-10 | $0.00 10-Q · filed 2020-12-10 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-12-10 | $0.00 10-Q · filed 2020-12-10 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |